SU3.1 | Blood Products and Transfusion Complications — Summary & Reflection

KEY TAKEAWAYS

Transfusion is lifesaving but hazardous, and safe practice rests on three pillars. First, component therapy: give only the fraction the patient lacks — packed red cells (2–6 °C, ~35–42 days) for anaemia and red-cell loss, platelets (20–24 °C with agitation, ~5 days) for thrombocytopenic bleeding, fresh frozen plasma (≤ −30 °C, ~1 year) for multiple-factor coagulopathy, and cryoprecipitate (fibrinogen, factor VIII, vWF, factor XIII) for hypofibrinogenaemia — all ABO/Rh-compatible and transfused within four hours. Second, the complications, classified as immunological (acute haemolytic from ABO incompatibility, FNHTR, allergic/anaphylactic, TRALI within six hours, delayed haemolytic) and non-immunological (TACO, bacterial contamination, transfusion-transmitted infection, and the metabolic complications of massive transfusion — citrate-induced hypocalcaemia, hyperkalaemia, hypothermia and dilutional coagulopathy, addressed by balanced ~1:1:1 resuscitation, warming and calcium monitoring). Third, prevention: correct grouping, a valid crossmatch and the bedside identity check, because the commonest fatal reaction is a clerical wrong-patient error caught only at the bedside, in the first minutes.

REFLECT

Think back to a transfusion you have seen given — on a surgical ward, in theatre, or in the emergency department. Was the product the right one for the patient's actual deficit, or was whole blood or red cells used where a specific component was indicated? How closely were the first 15 minutes observed, and would a dangerous reaction have been caught early? Picture yourself now responsible for a massively bleeding trauma patient: how would you anticipate and prevent the hypocalcaemia, hyperkalaemia, hypothermia and coagulopathy of massive transfusion, and how would understanding these mechanisms change the way you ask for and check blood for your next patient?